Pages that link to "Q51043785"

The following pages link to The Aberrant Behavior Checklist-Community: factor validity and effect of subject variables for adults in group homes. (Q51043785):

Displaying 37 items.

• Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism (Q28247116) (← links)
• Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. (Q31043571) (← links)
• Primary care of adults with developmental disabilities: Canadian consensus guidelines (Q34978203) (← links)
• FRAGILE X SYNDROME: PSYCHIATRIC MANIFESTATIONS, ASSESSMENT AND EMERGING THERAPIES (Q35013074) (← links)
• An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III. (Q35052627) (← links)
• Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability (Q35641750) (← links)
• Randomized Controlled Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder (Q35762259) (← links)
• Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment (Q35791185) (← links)
• Trajectories of early brain volume development in fragile X syndrome and autism (Q36192790) (← links)
• Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome (Q36549606) (← links)
• Lurasidone for the Treatment of Irritability Associated with Autistic Disorder (Q36674291) (← links)
• Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial (Q36694513) (← links)
• Longitudinal trajectories of aberrant behavior in fragile X syndrome (Q36763882) (← links)
• A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome (Q36996583) (← links)
• Assessing the Impact of Psychotropic Medication Changes on Challenging Behavior of Individuals with Intellectual Disabilities (Q37087389) (← links)
• Aberrant basal ganglia metabolism in fragile X syndrome: a magnetic resonance spectroscopy study (Q37155073) (← links)
• The Influence of Hyperactivity, Impulsivity, and Attention Problems on Social Functioning in Adolescents and Young Adults With Fragile X Syndrome (Q41322963) (← links)
• Supplementation of omega 3 fatty acids may improve hyperactivity, lethargy, and stereotypy in children with autism spectrum disorders: a meta-analysis of randomized controlled trials (Q42373848) (← links)
• Measurement tools and target symptoms/skills used to assess treatment response for individuals with autism spectrum disorder (Q44875509) (← links)
• Construct Validity of the Autism Impact Measure (AIM). (Q47554692) (← links)
• Psychometric properties of the obsessive compulsive inventory: child version in children and adolescents with obsessive-compulsive disorder (Q47605443) (← links)
• Altered Brain Network Segregation in Fragile X Syndrome Revealed by Structural Connectomics (Q48809270) (← links)
• An indirect examination of the function of problem behavior associated with fragile X syndrome and Smith-Magenis syndrome (Q48886204) (← links)
• Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study (Q50305958) (← links)
• The prevalence and incidence of mental ill-health in adults with autism and intellectual disabilities (Q50310504) (← links)
• Quality of life of adults with pervasive developmental disorders and intellectual disabilities (Q50310656) (← links)
• Factor analysis of restricted and repetitive behaviors in autism using the Autism Diagnostic Interview-R (Q50343891) (← links)
• Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale-revised for fragile X syndrome. (Q50344421) (← links)
• (Q50351273) (← links)
• De novo unbalanced translocation (4p duplication/8p deletion) in a patient with autism, OCD, and overgrowth syndrome. (Q52680610) (← links)
• Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents (Q59329374) (← links)
• Psychiatric comorbidities in autism spectrum disorder: A comparative study between DSM-IV-TR and DSM-5 diagnosis (Q60491791) (← links)
• Autism, spectrum or clusters? An EEG coherence study (Q64243031) (← links)
• Statins for Smith-Lemli-Opitz syndrome (Q90054585) (← links)
• Long-Term Effect of Therapeutic Horseback Riding in Youth With Autism Spectrum Disorder: A Randomized Trial (Q90652047) (← links)
• Factors that predict good Active Support in services for people with intellectual disabilities: A multilevel model (Q90709387) (← links)
• Association between epilepsy and challenging behaviour in adults with intellectual disabilities: systematic review and meta-analysis (Q99709850) (← links)